Key result
Study compares DOACs and warfarin for secondary stroke prevention in patients with LVEF ≤30%.
Answers are grounded in this paper and cite their sources.
May favor DOACs over warfarin for secondary prevention in LVEF ≤30%; hypothesis-generating, requiring confirmation before practice change.
To compare the effectiveness and safety of direct oral anticoagulants (DOACs) versus warfarin for secondary stroke prevention in patients with LVEF ≤30%.
No takes yet. Share an insight, caveat, or question.
Morsi et al. (2026) studied this question. Direct oral anticoagulants and warfarin are being compared for effectiveness and safety in secondary stroke prevention among patients with left ventricular ejection fraction ≤30%.
Synapse has enriched 10 related papers. Consider them for comparative context: